Investigational drug · Phase 2
MIV-818
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Metastases.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "MIV-818"
First trial start
2018
Sep 5, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MIV-818", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Intrahepatic Cholangiocarcinoma
- Liver Metastases
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "MIV-818" as an intervention, largest first.
MedivirIndustry
NCT03781934 · 53 participants · Start Sep 5, 2018 · Primary completion Jan 7, 2025
Drug: MIV-818 (fostroxacitabine bralpamide) + pembrolizumab; MIV-818 (fostroxacitabine bralpamide) + lenvatinib · For: Hepatocellular Carcinoma; Intrahepatic Cholangiocarcinoma; Liver Metastases
Sites: Antwerp, Belgium; Leuven, Belgium; Gyeonggi-do, South Korea · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 1a/1b Study of Fostroxacitabine Bralpamide (Fostrox) Monotherapy in Hepatocellular Carcinoma and Solid Tumor Liver Metastases.
Plummer R, Greystoke A, Naylor G, et al. · J Hepatocell Carcinoma 2024
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.